药理学腺苷受体激动剂/拮抗剂在血管生成中的治疗效力：现状与展望。
Therapeutic potency of pharmacological adenosine receptor agonist/antagonist in angiogenesis, current status and perspectives.
机构信息
Faculty of Medicine, Department of Clinical Biochemistry and Immunogenetic Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.
Faculty of Medicine, Department of Medical Physiology, Mashhad University of Medical Sciences, Mashhad, Iran.
出版信息
J Pharm Pharmacol. 2018 Feb;70(2):191-196. doi: 10.1111/jphp.12844. Epub 2017 Oct 23.
OBJECTIVES
Adenosine concentration significantly increases in tumour microenvironment contributing to tumorigenic processes including cell proliferation, survival, invasion and of special interest in this review angiogenesis.
KEY FINDINGS
This review summarizes the role of pharmacological adenosine receptor agonist and antagonist in regulating angiogenesis for a better understanding and hence a better management of angiogenesis-associated disorders.
SUMMARY
Depending upon the pharmacological characteristics of adenosine receptor subtypes, adenosine elicits anti- or pro-angiogenic responses in stimulated cells. Inhibition of the stimulatory effect of adenosine signalling on angiogenesis using specific pharmacological adenosine receptor agonist, and antagonist is a potentially novel strategy to suppress angiogenesis in tumours.
目的
腺嘌呤核苷浓度在肿瘤微环境中显著增加，有助于肿瘤发生过程，包括细胞增殖、存活、侵袭，特别是在本综述中提到的血管生成。
主要发现
本综述总结了药理学上的腺嘌呤核苷受体激动剂和拮抗剂在调节血管生成方面的作用，以便更好地理解和更好地管理与血管生成相关的疾病。
总结
根据腺嘌呤核苷受体亚型的药理学特性，腺嘌呤核苷在受刺激的细胞中引发抗血管生成或促血管生成反应。使用特定的药理学腺嘌呤核苷受体激动剂和拮抗剂抑制腺苷信号对血管生成的刺激作用，是抑制肿瘤血管生成的一种潜在的新策略。
Zotero 插件